Assembly Actions -
Lowercase Senate Actions - UPPERCASE |
|
---|---|
Jan 06, 2016 |
referred to health |
Jan 12, 2015 |
referred to health |
Assembly Bill A1525
2015-2016 Legislative Session
Sponsored By
CAHILL
Archive: Last Bill Status - In Assembly Committee
- Introduced
-
- In Committee Assembly
- In Committee Senate
-
- On Floor Calendar Assembly
- On Floor Calendar Senate
-
- Passed Assembly
- Passed Senate
- Delivered to Governor
- Signed By Governor
Actions
multi-Sponsors
Thomas Abinanti
James F. Brennan
William Colton
Clifford Crouch
2015-A1525 (ACTIVE) - Details
2015-A1525 (ACTIVE) - Bill Text download pdf
S T A T E O F N E W Y O R K ________________________________________________________________________ 1525 2015-2016 Regular Sessions I N A S S E M B L Y January 12, 2015 ___________ Introduced by M. of A. CAHILL -- Multi-Sponsored by -- M. of A. ABINAN- TI, BRENNAN, BROOK-KRASNY, CLARK, COLTON, CROUCH, CYMBROWITZ, ENGLE- BRIGHT, GALEF, GLICK, GOTTFRIED, GUNTHER, JAFFEE, MONTESANO, PAULIN, PERRY, ROSENTHAL, WEINSTEIN, WEPRIN -- read once and referred to the Committee on Health AN ACT to amend the public health law, in relation to prescription privacy THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. Legislative findings and intent. Prescribing health care professionals should have a reasonable expectation that when they prescribe a medication for a patient, that decision will not be made available to an outside third party. However, disclosure of individual identifying information about patients and prescribers enables pharma- ceutical companies to track the prescribing practices of physicians to target them for marketing, including gifts and payments. This marketing can distort prescribing practices to increase health care costs and undermine patient safety. The National Institutes of Health has found that nearly one-third of the increase in prescription drug prices over the last decade was attributable to marketing-induced shifts in prescribing practices. Published evidence shows that prescribers are often encouraged by sales representatives to prescribe medications in a manner that has not been approved by the Federal Food and Drug Adminis- tration. Neither the state nor any other entity has the resources to effec- tively counter targeted marketing campaigns that exceed hundreds of millions of dollars. The legislature finds that this legislation is necessary to protect health care professionals and their patients from the abuses of targeted marketing that are made possible by the disclosure of individual identi- fying information. EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets [ ] is old law to be omitted. LBD06242-01-5
Comments
Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.
Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.
Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.